Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5451]

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat...

Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma ( Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy )

Treating patients with multiple myeloma in the real world

Dr Ajai Chari and Prof Roman Hájek

Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or...

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients...

Dr Naval Daver - MD Anderson Cancer Center, Houston, USA

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )

New CAR T therapy for relapsed and refractory ALL

Dr Claire Roddie - University College London, London, UK

$New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )$

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

Prof Philippe Moreau - University of Nantes, Nantes, France

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk...

Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and...

Prof Efstathios Kastritis - University of Athens, Athens, Greece

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis ( Prof Efstathios Kastritis - University of Athens, Athens, Greece )

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

More from ecancer